期刊文献+

三维适形放疗联合替吉奥治疗42例局部复发直肠癌的临床观察 被引量:8

Three Dimensional-conformal Radiotherapy Combined with Tegafur chemotherapy for recurrent rectal cancer
下载PDF
导出
摘要 目的观察三维适形放疗联合替吉奥治疗局部复发直肠癌患者的近期疗效及治疗的安全性。方法 42例经病理证实的局部复发的直肠癌患者接受了全盆腔三维适形放疗(3-DCRT),DT46~50Gy/23~25F,后缩野至肿瘤区继续推量至DT64~66Gy/32~33F,同期接受替吉奥口服化疗,(40~60)mg/(m2.d),2次/d,连服3周,休1周,共2周期。结果疗效评价:CR4例(9.5%),PR30例(59.5%),SD7例(16.6%),PD0例(0%),总有效率(CR+PR)69%;疼痛症状缓解率为100%;全身况好转率76.2%。主要毒副反应为中性粒细胞减少、消化道反应、及末梢神经毒性,以Ⅰ~Ⅱ度为主,Ⅲ~Ⅳ度少见,全组中性粒细胞减少发生率为66.7%,恶心呕吐发生率为45.2%,腹泻发生率为28.6%,末梢神经毒性发生率为26.2%。结论 3-DCRT联合替吉奥方案的同期放化疗方案是局部复发直肠癌较好的治疗方法,其近期疗效确切、治疗的依从性高、毒副反应可耐受,值得临床应用。 Objective To evaluate the compliance and efficacy of Radiotherapy combined with Tegafur for recurrent rectal cancer.Methods Thirty two patients with recurrent rectal cancer received three dimensional-conformal radiotherapy(for 46~50 Gy/5 weeks and was boosted to the tumor 16~18 Gy/2 weeks,2 Gy/fraction,5 days/week) in combination with FOLFOX,every 3 weeks.Results The overall response rate was 69%,with CR 4(9.5%),PR 25(59.5%),SD 7(16.7%),PD 0(0%).The remission rate of pain and improvement rate of performance status were 100% and 72.6%.Treatment-related toxicity mainly showed at neutrocytopenia 、gastrointestinal reaction and peripheral neurotoxicity,main to Ⅰ~Ⅱ degree,the grade Ⅲ or IV rare.The whole group of neutropenia occurred at a rate of 66.7%,nausea and vomiting occurred at a rate of 45.2%,diarrhea incidence was 28.6%,peripheral neurotoxicity occurred at a rate of 26.2%.Conclusion Combination of three Dimensional-conformal radiotherapy with the improved scheme of tegafur is active in recurrent rectal cancer,It is worthy of clinical application.
出处 《中国实用医药》 2012年第8期6-8,共3页 China Practical Medicine
关键词 三维适形放疗 直肠癌 同期放化疗 替吉奥 Three Dimensional-conformal Radiotherapy Rectal cancer Chemoradiotherapy Tegafur
  • 相关文献

参考文献7

二级参考文献35

  • 1钱立庭,金大伟,刘新帆,李晔雄,宋永文,余子豪.直肠癌术后辅助性放疗不同照射技术的剂量学研究[J].中华放射肿瘤学杂志,2005,14(6):483-486. 被引量:51
  • 2向作林,吴铮,陈刚,曾昭冲,李文如.三维适形放疗联合XELOX方案治疗局部晚期和术后复发性直肠癌[J].临床肿瘤学杂志,2006,11(1):29-31. 被引量:9
  • 3周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,1998.463.
  • 4贾博琦,鲁云兰.现代临床使用药物手册.北京:北京医科大学出版社,2001:767-770.
  • 5[3]DillmanRO,HemdonJ,SearrenSL,et al.Improved survival in stage 3 non -small cell lung cancer.seven-year follow-up of cancer and leudemia group B (CALGB)8433 trial[J].J Natal Cancer Inst,1996,88(17):1210-1216.
  • 6Quirke P,Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG C016 randomised clinical tria [ J ]. Lancet ,2009, 373 (9666) :821 - 828.
  • 7Sebag-Montefiore D, Stephens R J, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial [ J ].Lancet,2009, 373 (9666) : 811 - 820.
  • 8Bosset JF, Calais G, Daban A, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance, report of 22921 randomised trial conducted by the EORTC Radiotherapy Group[ J]. Eur J Cancer, 2004, 40(2) :219 -224.
  • 9Gerard JP, Conroy T, Bonnetain F,et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Resuhs of FFCD 9203 [ J]. J Clin Oncol, 2006,24 (28) :4620 - 4625.
  • 10Klautke G, Fietkau R. Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review [JJ. Int J Colorectal Dis, 2007,22(5) :457 -465.

共引文献77

同被引文献57

  • 1宋永文,钱立庭,李晔雄,刘新帆,金晶,王维虎,刘跃平,王淑莲.直肠癌的预后因素和治疗失败原因分析[J].中国肿瘤,2006,15(7):484-487. 被引量:6
  • 2郑安平,赵一电,赵福军,孙荣刚,张广彬,王东果.放化疗综合治疗直肠癌术后局部复发38例疗效分析[J].实用癌症杂志,2007,22(4):391-392. 被引量:4
  • 3殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2007:546-574.
  • 4罗健.癌症疼痛和姑息治疗//孙燕,石远凯,主编.临床肿瘤内科手册(第5版).北京:人民卫生出版社,2008:251-287.
  • 5THERASSE P, ARBUCK S G, EISENHAUER E A, et al. New guidelines to evaluate the response to treatment in solid tumors [J]. JNCI ,2000 ,92(3) :205-216.
  • 6OHTSU A,BABA H,SAKATA Y,et al. Phase n study of S-1 , a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma study Group [J]. Br J Cancer, 2000, 83(2) :141-145.
  • 7NAKATA E,FUKUSHINA M,TAKAI Y,et al. S-l,an oral fluoropyrimidine, enhances radiation response of DLD-l/FU human colon cancer xenografts resistant to 5 - FU [J] . Oncol Rep,2006,16(3) :465-471.
  • 8WADA H,NEMOTO K,NOMIYA T,et al. A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer [J] . Int J Clin Oncol, 2013 , 18 ( 2) : 273-278.
  • 9HONG Y S,LEE J L,PARK J H,et al. Phase I study of preoperative chemoradiation with S-1 and Oxaliplatin in patients with locally advanced resectable rectal cancer [J] . Int J Radiat Oncol BioI Phys ,2011 ,79(3) :684-689.
  • 10KURIU Y, KOKUBA Y , MURA YAMA Y, et al. Neoadjuvant chemoradiotherapy for locally advanced rectalcancer [J]. Gan To Kagaku Ryoho,2012 ,39(12) :1951-1953.

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部